Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

Executive Summary

CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.


Related Content

Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps
CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
Room For Innovative Switches Could Lurk In Existing FDA Framework
FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst